Care Funding Check

Multiple Sclerosis & NHS Continuing Healthcare

MS care needs — whether fluctuating or progressive — can qualify for full NHS funding

Multiple sclerosis affects people differently. Relapsing-remitting MS brings unpredictable relapses with acute nursing needs. Progressive MS brings gradual but compounding deterioration. Both presentations can produce the complex, clinically significant needs that NHS Continuing Healthcare is designed to fund.

Last reviewed June 2026 · Based on the National Framework for NHS Continuing Healthcare (revised 2022).

150,000+
People living with MS in the UK (MS Trust, 2024)
3 in 4
People with MS experience significant fatigue affecting daily function
~50%
Historically needed walking help within 15 years — before modern disease-modifying therapies
£67,600
Average annual care home cost for self-funders

Relapsing or progressive: two routes to eligibility

Multiple sclerosis is a neurological condition involving demyelination of nerve fibres, causing progressive or relapsing impairment across motor, sensory, cognitive, and autonomic systems. The clinical picture varies significantly between individuals and between disease types — but in both relapsing-remitting and progressive MS, the level of care required in the later stages can be substantial.

The CHC framework captures two features of MS particularly well: unpredictability and deterioration. In relapsing-remitting MS, the unpredictability of relapses — which can involve acute nursing needs that exceed what a care home can provide without specialist input — is directly relevant to CHC scoring. In progressive MS, the trajectory of deterioration means that needs which are currently manageable will become more complex, and assessors should be considering both the current and near-future picture.

The domains MS most affects

Mobility

MS-related spasticity, weakness, and balance impairment create a high-complexity mobility picture. Transfers, pressure area care, and spasm management require consistent skilled nursing input. Falls risk is significant and must be accurately assessed.

Continence

Bladder dysfunction affects around 80% of people with MS. Catheter management, urinary tract infection risk, and bowel dysfunction create ongoing nursing needs that frequently require skilled clinical management rather than basic care assistance.

Fatigue

While fatigue does not map to a single DST domain, it runs through the entire assessment. MS-related fatigue is a neurological symptom, not simply tiredness — it can cause sudden functional collapse and must be evidenced across the relevant domains, particularly Mobility and Drug Therapies.

Cognition

Cognitive impairment affects an estimated 40–70% of people with MS, depending on how it is assessed, and can involve working memory, processing speed, and attention. Where cognitive decline is present, its effect on the person’s ability to manage their own care and safety is clinically significant.

Drug therapies and medication

Disease-modifying therapies and symptom management medications in MS can involve complex administration, monitoring requirements, and side-effect management. Where specialist nursing input is required for medication management, this domain should be scored accordingly.

Evidencing an MS case

Evidence that carries weight in MS CHC assessments:

  • Neurology clinic letters documenting disease course, EDSS (Expanded Disability Status Scale) score, and current functional level
  • MS nurse specialist records, where involved
  • Relapse history and documentation of acute presentations, including hospital admissions
  • Bladder and bowel assessment records, including catheter care documentation
  • Physiotherapy and occupational therapy assessments
  • Fatigue impact scale or equivalent functional assessment
  • A carer’s account of the person’s needs across a full week, including worst presentations

Where MS assessments fall short

Failing to assess the relapsing-remitting picture properly. An assessment conducted between relapses, when the person’s presentation may be relatively stable, does not reflect the clinical reality of their condition. The unpredictability and severity of relapses must be evidenced and presented — this is where carer accounts and relapse records are critical.

Treating fatigue as a personal characteristic rather than a symptom. MS fatigue is a neurological symptom with direct implications for care needs and safety. Assessors who note fatigue but do not reflect it in domain scoring are underassessing the case.

Underscoring continence. Catheter management and complex continence care in MS are frequently scored at Moderate when the level of nursing skill and frequency of intervention justifies Severe. The clinical complexity of catheter management — including infection risk, blocked catheter management, and suprapubic catheter care — must be properly evidenced.

Sources & further reading

The guidance on this page is grounded in the National Framework and reputable clinical sources. Always check the current version of each:

Frequently asked questions

Can someone with relapsing-remitting MS qualify for NHS Continuing Healthcare?

Yes. Relapsing-remitting MS produces unpredictable, acute care needs during relapses that can constitute a primary health need — particularly where hospital-level nursing input is required at home or in a care setting. Between relapses, the person’s baseline needs may also be significant enough to qualify. The National Framework weights unpredictability explicitly, which works in favour of relapsing-remitting presentations. A CHC assessment should consider both the baseline and the relapse picture.

Does progressive MS qualify more easily than relapsing-remitting MS?

Not necessarily — the framework assesses current needs, not diagnosis type. Progressive MS does produce a more predictable deterioration trajectory, which means the unpredictability weighting is less relevant. However, the sheer level of care required in advanced progressive MS — across mobility, continence, cognition, and drug therapy management — frequently meets the primary health need threshold on the basis of complexity and intensity alone. Both presentations can qualify; the evidence strategy differs.

What is the EDSS score and does it affect CHC eligibility?

The Expanded Disability Status Scale (EDSS) is a standardised measure of neurological disability in MS, scored from 0 to 10. It is a useful reference point for evidencing the level of disability, but it does not directly determine CHC eligibility. What matters is how the person’s needs translate into specific CHC domain scores — an EDSS of 7 or above typically corresponds to significant care needs across multiple domains, but the domain-level evidence, not the EDSS number alone, is what drives the eligibility decision.

Find out if your loved one may be eligible

Start free check →